Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Labeling Information | Drug Products

Labeling Information | Drug Products

                        Pregnancy and Lactation Labeling (Drugs) Final Rule Home
          Drugs
          Development & Approval Process | Drugs
          Development Resources
          Labeling Information | Drug Products
          Outline of Section 8.1 – 8.3 on Drug LabelingLabeling Information | Drug Products Outline of Section 8.1 – 8.3 on Drug Labeling
  
  	
    Share
    Post
    Linkedin

    Email
    PrintView and print Outline of Section 8.1 – 8.3 on Drug Labeling (PDF - 18KB)*As proposed in the Draft Guidance***FORMATTING**Subsection numbers and titles in the Full Prescribing Information (FPI) must be bolded (e.g., **8.1 Pregnancy**) (§ 201.57(d)(7)). In addition, unique to the PLLR is the requirement for the inclusion of specific subheadings and headings under subheadings within subsections (e.g., Risk Summary). Subheading titles within these subsections should be italicized and/or underlined, and heading titles should be either italicized or underlined, and the approach used should be consistent throughout the labeling. Additional subdivisions of information are not recommended.8.1 Pregnancy**Pregnancy Exposure Registry**(omit if not applicable)If there is a scientifically acceptable pregnancy exposure registry for the drug, the following statement must appear:“There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to (name of drug) during pregnancy.”The statement must be followed by contact information needed to enroll in or to obtain information about the registry.**Risk Summary**(required subheading)Provides ‘risk statements’ that describe for the drug the risk of adverse developmental outcomes based on all relevant human, data, animal data and the drug’s pharmacology.When applicable, risk statements must include a cross-reference to additional details in the relevant portion of the Data subheading in the Pregnancy subsection.**Clinical Considerations**(omit if none of the headings are applicable)Provides information to further inform prescribing and risk-benefit counseling.Relevant information is presented under the following 5 subheadings:*Disease-associated maternal and/or embryo/fetal risk (omit if not applicable)**Dose adjustments during pregnancy and the postpartum period* (omit if not applicable)*Maternal adverse reactions* (omit if not applicable)*Fetal/Neonatal adverse reactions* (omit if not applicable)*Labor or delivery* (omit if not applicable)**Data** (omit if none of the headings are applicable)Describes the data that provide the scientific basis for the information presented in the Risk Summary and Clinical Considerations*Human Data* (omit if not applicable)*Animal Data* (omit if not applicable)8.2 LactationReplaces the Nursing Mothers subsection**Risk Summary**(required subheading)Summarizes information on the presence of a drug and/or its active metabolite(s) in human milk, the effects of a drug and/or its active metabolite(s) on the breastfed child, and the effects of a drug and/or its active metabolite(s) on milk production**Clinical Considerations**(omit if not applicable)Provides information to further inform prescribing and risk-benefit counseling.Minimizing exposureMonitoring for adverse reactions**Data** (omit if not applicable)Describes the data that provide the scientific basis for the information presented in the Risk Summary and Clinical Considerations8.3 Females and Males of Reproductive Potential(omit if none of the subheadings are applicable)Includes information for these populations whenThere are recommendations or requirements for pregnancy testing and/or contraception before, during, or after drug therapy; and/orThere are human and/or animal data suggesting drug-associated effects on fertility**Pregnancy Testing**(omit if not applicable)**Contraception** (omit if not applicable)**Infertility** (omit if not applicable)

                                                                                  Content current as of:
      12/03/2014Labeling Information | Drug Products

          
                        Pregnancy and Lactation Labeling (Drugs) Final Rule
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop